Table of Contents  

Hromadnikova: The exploitation of extracellular nucleic acids in diagnosis and prediction of placental insufficiency-related complications

Introduction

Pre-eclampsia and intrauterine growth restriction (IUGR) are major causes of maternal and perinatal morbidity and mortality.1,2 Pre-eclampsia affects approximately 2–5% of pregnancies, and usually develops after 20 weeks of gestation.2 It is characterized by chronic or gestational hypertension combined with proteinuria caused by defective placentation resulting from inadequate uteroplacental blood perfusion and ischaemia.3,4 Recent findings suggest that pre-eclampsia should be subdivided according to gestational age at the time of required delivery into early pre-eclampsia (before 34 weeks of gestation), intermediate pre-eclampsia (at 34–37 weeks of gestation) and late pre-eclampsia (after 37 weeks of gestation). This enables us to distinguish more clearly between women at high, low and no risk of pre-eclampsia as early as possible, optimally around 11–13 weeks of gestation,5,6 when prophylactic treatment may be considered and eventually started. A meta-analysis found that low-dose aspirin therapy (50–150 mg of acetylsalicylic acid daily) initiated in early pregnancy (before 16 weeks of gestation) was associated with a significant reduction in the incidence and severity of pre-eclampsia, IUGR and preterm birth (before 34 weeks of gestation) in women identified to be at moderate or high risk of pre-eclampsia using various inclusion criteria, mostly anamnestic maternal risk factors and subsequently abnormal uterine artery Doppler velocimetry.7 It is believed that low-dose aspirin could inhibit thromboxane-mediated vasoconstriction and thereby prevent endothelial dysfunction and activation of the platelet and clotting system.8,9

The underlying causes of pre-eclampsia and IUGR have not yet been discovered. Nevertheless, it has been clearly demonstrated that placenta is continuously remodelled during normal placental development, and establishment of an optimal balance between trophoblast proliferation and apoptosis is crucial.10 As a result, extracellular nucleic acids of both fetal and placental origin,11,12 packed in trophoblast-derived apoptotic bodies,1315 may be detected in the maternal circulation during the course of normal gestation. Increasing levels of circulating fetal DNA with advancing gestation reflect the growth of the placenta.12 In addition, the placenta sheds syncytiotrophoblast microparticles, which are also released into the maternal circulation.16

Placental insufficiency-related pregnancy complications are associated with excessive levels of extracellular fetal DNA. A hypoxic environment is likely to be responsible for inducing trophoblast cell death and increased shedding of placental debris into the maternal circulation.15,16

In this article, recent advances in this field demonstrated by our group are reviewed, with a focus on the diagnostic potential of particular markers and their implementation in algorithms to predict and diagnose placental insufficiency-related complications by quantification of extracellular nucleic acids in the maternal circulation.

Quantification of extracellular DNA in maternal circulation – discrimination between normal pregnancies and placental insufficiency-related complications

Our previous extracellular DNA quantification studies1719 proved to have high accuracy for differentiation between normal pregnancies and those associated with the onset of pre-eclampsia with or without IUGR (RASSF1A, 93.1%; SRY, 93.6%; and GLO, 92.1%) and/or IUGR itself (RASSF1A, 91.6%; SRY, 92.5% and GLO, 89.5%).19

We also reported that the DYS-14 sequence is not an optimal marker for extracellular fetal DNA quantification because of considerable variation in DYS-14 copy numbers in males and discrepancies in DYS-14 copy numbers between extracellular fetal DNA and the original fetal genome.17

Quantitative aberrations of extracellular DNA in maternal circulation as risk markers for predicting placental insufficiency-related complications

Our next pilot study demonstrated elevation of extracellular DNA in three out of five (SRY), one out of eight (hypermethylated RASSF1A) and four out of eight (GLO) patients at various stages of gestation ranging from 26 weeks to 2 weeks before the onset of clinical symptoms of pre-eclampsia (n = 4), IUGR (n = 3) and/or chronic placentopathy causing hypoxia. SRY and GLO markers provided superior results to the hypermethylated RASSF1A sequence.19

Identification of placenta-specific micro-RNAs in maternal circulation

The goal of our recent study20,21 was to identify extracellular placenta-specific micro-RNAs in the maternal circulation. We focused mainly on testing those micro-RNAs which had been shown to be placenta specific according to the miRNAMap database22 and a study presented by Liang et al.23 Finally, we introduced a panel of seven extracellular placenta-specific micro-RNAs (miR-516-5p, miR-517*, miR-518b, miR-520a*, miR-520h, miR-525, miR-526a) with the greatest potential to enable non-invasive monitoring throughout gestation of the growth and condition of the placenta in all pregnancies without interference from expression of micro-RNAs arising from maternal peripheral blood and tissues. Absolute and relative quantification approaches revealed significant increases in extracellular placenta-specific micro-RNAs level over time in normally progressing pregnancies.20,21

Extracellular micro-RNAs may differentiate between normal pregnancies and placental insufficiency in early gestation

The data derived from our pilot study demonstrated that extracellular placenta-specific micro-RNA levels and their expression profile (miR-516–5p, miR-517*, miR-518b, miR-520a*, miR-520h, miR-525 and miR-526a) did not differ significantly between normal and complicated pregnancies at the time of pre-eclampsia and/or IUGR onset.24,25 Nevertheless, significant elevation of extracellular micro-RNAs was observed during early gestation (12–16 weeks) in all pregnancies in which pre-eclampsia and/or IUGR later developed.

To provide safe prenatal monitoring, extracellular micro-RNAs quantification studies should be performed using only fresh samples with a storage life of < 2 months.24,25

Conclusion

We have developed a panel of extracellular placenta-specific micro-RNA markers that might be reliably detected in the maternal circulation during the course of gestation. We have demonstrated that the level of micro-RNA markers increases continuously in the maternal circulation with advancing gestation, reflecting the growth of the placenta. Despite the fact that placental insufficiency-related complications have been shown to be associated with excessive levels of extracellular fetal and total DNA in the maternal circulation, neither absolute nor relative quantification of placenta-specific extracellular micro-RNAs was able to differentiate between normal and complicated pregnancies at the time of pre-eclampsia and/or IUGR onset. Interestingly, the experiments pioneered by our group, evaluating the diagnostic potential of the newly identified micro-RNA markers to predict the onset of placenta insufficiency-related complications as early as possible, provided promising results. Significant elevation of extracellular placenta-specific micro-RNAs was observed at 12–16 weeks of gestation in all pregnancies with later onset of pre-eclampsia and/or IUGR, whereas elevation of extracellular fetal (hypermethylated RASSF1A and SRY sequences) and total DNA (GLO sequence) was observed in only some of these patients. Based on the results of this pilot study, a large-scale analysis was initiated. The panel of selected extracellular micro-RNAs is being validated for incorporation into first-trimester screening to identify high-risk pregnancies. These data strongly support the need for a more detailed exploration of extracellular micro-RNAs in the maternal circulation with a view to their routine assessment in everyday practice and recognition as potential biomarkers for placental insufficiency-related complications.

Acknowledgement

This work was supported by project grant MSM 0021620806 and PRVOUK P32.

References

1. 

World Health Organization International Collaborative Study of Hypertensive Disorders in Pregnancy. Geographic variation in the incidence of hypertension in pregnancy. Am J Obstet Gynecol 1988; 158:80–3.

2. 

Khan KS, Wojdyla D, Say L, et al. WHO analysis of causes of maternal death: a systematic review. Lancet 2006; 367:1066–74. http://dx.doi.org/10.1016/S0140-6736(06)68397-9

3. 

ACOG Committee on Practice Bulletins – Obstetrics. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Obstet Gynecol 2002; 99:159–67.

4. 

Khong TY, De Wolf F, Robertson WB, et al. Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants. Br J Obstet Gynaecol 1986; 93:1049–59.http://dx.doi.org/10.1111/j.1471-0528.1986.tb07830.x

5. 

Akolekar R, Syngelaki A, Sarquis R, et al. Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11–13 weeks. Prenat Diagn 2011; 31: 66–74.http://dx.doi.org/10.1002/pd.2660

6. 

Poon LC, Akolekar R, Lachmann R, et al. Hypertensive disorders in pregnancy: screening by biophysical and biochemical markers at 11–13 weeks. Ultrasound Obstet Gynecol 2010; 35:662–70.

7. 

Bujold E, Roberge S, Lacasse Y, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 2010; 116: 402–14.http://dx.doi.org/10.1097/AOG.0b013e3181e9322a

8. 

Thorp JA, Walsh SW, Brath PC. Low-dose aspirin inhibits thromboxane, but not prostacyclin, production by human placental arteries. Am J Obstet Gynecol 1988; 159:1381–4.

9. 

Rennie J, Thornton JG, Hughes R, et al. Aspirin and pre-eclampsia. Lancet 1986; 1: 328–9.http://dx.doi.org/10.1016/S0140-6736(86)90865-2

10. 

Nelson DM. Apoptotic changes occur in syncytiotrophoblast of human placental villi where fibrin type fibrinoid is deposited at discontinuities in the villous trophoblast. Placenta 1996; 17: 387–91.http://dx.doi.org/10.1016/S0143-4004(96)90019-3

11. 

Lo YM, Corbetta N, Chamberlain PF, et al. Presence of fetal DNA in maternal plasma and serum. Lancet 1997; 350: 485–7.http://dx.doi.org/10.1016/S0140-6736(97)02174-0

12. 

Lo YM, Tein MS, Lau TK, et al. Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis. Am J Hum Genet 1998; 62: 768–75.http://dx.doi.org/10.1086/301800

13. 

Huppertz B, Kingdom JC. Apoptosis in the trophoblast – role of apoptosis in placental morphogenesis. J Soc Gynecol Invest 2004; 11:353–62.http://dx.doi.org/10.1016/j.jsgi.2004.06.002

14. 

Oudejans CB, Tjoa ML, Westerman BA, et al. Circulating trophoblast in maternal blood. Prenat Diagn 2003; 23:111–16.http://dx.doi.org/10.1002/pd.539

15. 

Orozco AF, Bischoff FZ, Horne C, et al. Hypoxia-induced membrane-bound apoptotic DNA particles: potential mechanism of fetal DNA in maternal plasma. Ann N Y Acad Sci 2006; 1075:57–62.http://dx.doi.org/10.1196/annals.1368.007

16. 

Reddy A, Zhong XY, Rusterholz C, et al. The effect of labour and placental separation on the shedding of syncytiotrophoblast microparticles, cell-free DNA and mRNA in normal pregnancy and pre-eclampsia. Placenta 2008; 29:942–9.http://dx.doi.org/10.1016/j.placenta.2008.08.018

17. 

Hromadnikova I, Benesova M, Zejskova L. The effect of DYS-14 copy number variations on extracellular fetal DNA quantification in maternal circulation. DNA Cell Biol 2009; 28:351–8.http://dx.doi.org/10.1089/dna.2009.0855

18. 

Zejskova L, Jancuskova T, Kotlabova K, et al. Feasibility of fetal-derived hypermethylated RASSF1A sequence quantification in maternal plasma – next step towards reliable non-invasive prenatal diagnostics. Exp Mol Pathol 2010; 89:241–7.http://dx.doi.org/10.1016/j.yexmp.2010.09.002

19. 

Hromadnikova I, Zejskova L, Kotlabova K, et al. Quantification of extracellular DNA using hypermethylated RASSF1A, SRY, and GLO sequences – evaluation of diagnostic possibilities for predicting placental insufficiency. DNA Cell Biol 2010; 29: 295–301.http://dx.doi.org/10.1089/dna.2009.0971

20. 

Hromadníková I, Kotlabová K, Jirásek JE, et al. Detection of placenta-specific microRNAs in maternal circulation. Ceska Gynekol 2010; 75:252–6.

21. 

Kotlabova K, Doucha J, Hromadnikova I. Placentalspecific microRNA in maternal circulation – identification of appropriate pregnancy associated microRNAs with diagnostic potential. J Rep Immunol 2011; 89:185–91.http://dx.doi.org/10.1016/j.jri.2011.02.006

22. 

miRNA Map. Department of Biological Science and Technology, Institute of Bioinformatics National Chiao Tung University, Hsinchu, Taiwan (available from:http://mirnamap.mbc.nctu.edu.tw/).

23. 

Liang Y, Ridzon D, Wong L, et al. Characterization of microRNA expression profiles in normal human tissues. BMC Genomics 2007; 8:166.http://dx.doi.org/10.1186/1471-2164-8-166

24. 

Hromadnikova I, Kotlabova K, Doucha J, et al. Absolute and relative quantification of placental specific microRNAs in maternal circulation with placental insufficiency related complications. In: Proceedings of the 5th International qPCR Symposium, Freising, Germany, 2011.

25. 

Hromadnikova I, Kotlabova K, Doucha J, et al. Absolute and relative quantification of placental specific microRNAs in maternal circulation with placental insufficiency related complications. J Mol Diagn 2012; 14:160–7.





Add comment 





Home  Editorial Board  Search  Current Issue  Archive Issues  Announcements  Aims & Scope  About the Journal  How to Submit  Contact Us
Find out how to become a part of the HMJ  |   CLICK HERE >>
© Copyright 2012 - 2013 HMJ - HAMDAN Medical Journal. All Rights Reserved         Website Developed By Cedar Solutions INDIA